Efficacy of Transcutaneous Electrical Acupoint Stimulation on Modulating Upper Extremity Sympathetic Skin Response in Alleviating Cancer Survivors With Chemotherapy-Induced Peripheral Neuropathy: A Propensity Score-Matched Cohort Study
Open Access
- 1 January 2025
- journal article
- research article
- Published by Taylor & Francis in Journal of Pain Research
- Vol. ume 18, 293-303
Abstract
Objective: Chemotherapy-induced peripheral neuropathy (CIPN) is a common side effect of chemotherapy and it is currently intractable We compared the efficacy of transcutaneous electrical acupoint stimulation (TEAS) against non-TEAS groups and investigated the variables that predict effective relief of upper extremity pain in cancer survivors with CIPN. Methods: We retrospectively collected data of cancer survivors who developed CIPN between May 2017 to March 2022. All eligible CIPN patients were divided into TEAS group (received TEAS) and non-TEAS group (did not receive TEAS) in our department. A 1:1 ratio propensity score matching (PSM) was used to balance the baseline features. The change of numerical rating scale (NRS), Short-Form McGill Pain Questionnaire-2 (SF-MPQ-2), and sympathetic skin response (SSR) parameters are all assessed after treatment. The procedure was considered a clinically effective relief if the patients’ NRS scores were reduced by 50% or more, and overall patients with effective relief were all counted after treatment. Furthermore, a multivariable logistic regression model was utilized to evaluate the predictors of effective relief following CIPN treatment. Results: : A total of 102 cancer survivors with CIPN were analyzed after PSM (51 in each group). The change of NRS, SF-MPQ-2, SSR latency and SSR amplitude in TEAS group were significantly higher than those in non-TEAS group at 3 weeks after therapy (all P< 0.01). In addition, the effective relief rate was significantly higher in TEAS group than in non-TEAS group (P=0.026). Multivariate logistic regression on the total study cohort showed that TEAS group (OR 2.783, P = 0.025) and the baseline SSR amplitude of the upper extremity < 1265 μV (OR 12.191, P = 0.000) were independent predictive factors for the clinical efficacy. Conclusions: : TEAS significantly decreased the severity of CIPN. TEAS group and baseline SSR amplitude of the upper extremity < 1265 μV were the independent predictive factors for the clinical efficacy after treatment.Keywords
This publication has 46 references indexed in Scilit:
- Transcutaneous electrical acupoint stimulation for cancer-related pain management in patients receiving chronic opioid therapy: a randomized clinical trialSupportive Care in Cancer, 2023
- Evidence-Based Treatment of Pain in Chemotherapy-Induced Peripheral NeuropathyCurrent Pain and Headache Reports, 2023
- Efficacy and Safety of Transcutaneous Electrical Acupoint Stimulation (TEAS) As An Analgesic Intervention for Labor Pain: A Network Meta-analysis of Randomized Controlled TrialsPain and Therapy, 2023
- Impact of acupuncture and integrative therapies on chemotherapy‐induced peripheral neuropathy: A multicentered, randomized controlled trialCancer, 2022
- Oxaliplatin-induced peripheral neuropathy: clinical features, mechanisms, prevention and treatmentJournal of Neurology, 2020
- Effect of Acupuncture vs Sham Procedure on Chemotherapy-Induced Peripheral Neuropathy SymptomsJAMA Network Open, 2020
- Taxane-induced peripheral neuropathy: differences in patient report and objective assessmentSupportive Care in Cancer, 2020
- Exercise-based rehabilitation for cancer survivors with chemotherapy-induced peripheral neuropathySupportive Care in Cancer, 2019
- Wireless transcutaneous electrical nerve stimulation device for chemotherapy-induced peripheral neuropathy: an open-label feasibility studySupportive Care in Cancer, 2018
- Sympathetic skin responseClinical Autonomic Research, 2003